Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-2: selumetinib plus docetaxel versus placebo plus docetaxel in second-line advanced non-small cell lung cancer
2012-003622-25Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Selumetinib + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Oct 2012; status: completed.
02
Drugs
selumetinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2012-003622-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003622-25.